what are we doing?
Story
Since millions of years ago fitohormones (e.g. auxins) have been reprograming TIR1 E3 ubiquitin ligase to change its ubiquitylation and degradation specificity.
Captor Therapeutics is a biopharmaceutical company focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.
Targeted Protein Degradation (TPD) combats the therapeutic limits of small molecules with overcoming drug resistance and uncoupling their pharmacokinetics from pharmacodynamics. Breakthrough TPD technology allows degradation of virtually any intracellular protein including the so-called “undruggable proteome”.
Captor Therapeuticsis a Swiss-Polish company with offices in Basel, Switzerland and operations in state-of-the-art laboratories in Wroclaw, Poland. Our integrated competencies and expertise in biology and chemistry allow us to perform all stages of early drug development.
Since millions of years ago fitohormones (e.g. auxins) have been reprograming TIR1 E3 ubiquitin ligase to change its ubiquitylation and degradation specificity.
Kenten J. and Roberts S. filed a patent application for compounds activating ubiquitination of a target protein. An idea of Ubiquitin Proteasome System modulation emerged.
Proof of Principle - targeted protein degradation with peptidic bifunctional moleculewas reported (Sakamoto K. et al., PNAS).
Nobel Prize in Chemistry was awarded for the discovery of ubiquitin-mediated protein degradation (Aaron Ciechanover, Avram Hershko and Irwin Rose).
First small molecule bifunctional degrader was reported (Smith A. et al., Bioorg. Med. Chem. Lett.).
Cereblon E3 ubiquitin ligase complex was identified as thalidomide’s target. The discovery fuelled progress in a Targeted Protein Degradation technology (Ito T. et al., Science).
Obterons™ at Captor Therapeutics – direct degraders inspired by nature.
Thanks to our expertise in targeted protein degradation we take a multi-faceted approach to eliminate pathological proteins. Our technology consists of bifunctional molecules and direct degraders.
Our proprietary Obteron™ platform enables the robust discovery of therapeutic compounds with good biopharmaceutical properties. These compounds lead to efficient protein degradation via proteasome and/or autophagosome.
Supported by over 44 mln EUR from European grants and private investors, we are currently working on several projects aiming at (1) advancement of a protein degradation platform and (2) development of first-in-class therapeutics for autoimmune and oncological indications.
Click the button below to expand panel with job offers to find an offer that interests you and submit an application to become one of us!
Pawel Dobrzański, an international expert in molecular biology and drug development, will support our team!
Captor Therapeutics S.A. announces the appointment of Tom Shepherd, Ph.D., as Chief Executive Officer
Focused on Targeted GPCR Degradation as Novel Approach for Drug Design
We have been selected as one of the „Scrip’s 10 To Watch” companies at #BIOEurope Digital 2020!
We have received over 27 M PLN grant for a new project!
A new grant will support...
Our review on protein degradation technology has been published in "Technology Transfer and Entrepreneurship"...
Discovery and development of a new clinical drug candidate in the treatment of hepatocellular carcinoma...
Captor Therapeutics Inc
ul. Duńska 11
54-427 Wrocław, Poland
Captor Therapeutics GmbH
Gewerbestrasse 24
4123 Allschwil, Switzerland